Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84677 trials found · Page 31 of 4234
-
New drug combo aims to protect the brain after a ruptured aneurysm
Disease control Not yet recruitingThe CASH study is a randomized, double-blind, placebo-controlled trial evaluating whether adding cilostazol to standard nimodipine therapy improves neurological outcomes in patients with aneurysmal subarachnoid hemorrhage (aSAH). The primary objective is to assess functional outc…
Phase: PHASE3 • Sponsor: Centre Hospitalier St Anne • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
Could a light helmet slow Alzheimer's? major trial seeks answers
Disease control Recruiting nowThis study is a multicenter, randomized, double-blind, placebo (sham device)-controlled clinical trial. A total of 320 patients with mild to moderate Alzheimer's disease (AD) are planned to be enrolled. Central stratified block randomization will be applied, with stratification …
Phase: PHASE3 • Sponsor: Danyang Huichuang Medical Equipment Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
15-Year watch: tracking the future of Gene-Edited patients
Disease control Recruiting nowThis is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study …
Sponsor: Beam Therapeutics Inc. • Aim: Disease control
Last updated Apr 22, 2026 21:13 UTC
-
First gene therapy trial offers hope for babies on ventilators
Disease control Recruiting nowX-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM. The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Gene Therapies • Aim: Disease control
Last updated Apr 20, 2026 16:19 UTC
-
New gentler treatment tested for aggressive leukemia
Disease control Not yet recruitingStudy on the Efficacy and Safety of a Reduced-Toxicity Conditioning Regimen Containing Thiotepa and Melphalan in Patients with Blast Phase Chronic Myeloid Leukemia
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New drug trial offers hope for Tough-to-Treat lung cancer patients
Disease control Recruiting nowThe main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Phase: PHASE3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Personalized vaccine trial aims to supercharge immune system against lung cancer
Disease control Recruiting nowResearchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New Triple-Drug attack on advanced bladder cancer enters final testing phase
Disease control Recruiting nowThe purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and p…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
New hope for blood cancer patients: experimental combo aims to wipe out leukemia more effectively
Disease control Recruiting nowThis phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induc…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Apr 13, 2026 20:08 UTC
-
Spinal implant trial aims to get SCI patients back on their feet
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety and effectiveness of Epidural Electrical Stimulation (EES) combined with rehabilitation training for the reconstruction of walking in patients with chronic spinal cord injury (SCI) classified as AIS C-D. The main questions…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
One-Shot cell therapy trial aims to reset immune system in devastating nerve diseases
Disease control Recruiting nowThis single-arm, open-label investigator-initiated trial (IIT) evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05 in patients with autoimmune neurological diseases, including Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inf…
Phase: EARLY_PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Engineered immune cells target Tough-to-Treat blood cancer
Disease control Recruiting nowDALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of …
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Apr 06, 2026 14:15 UTC
-
Major trial aims to shield seniors from dangerous gut infection
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. diffici…
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 23, 2026 15:18 UTC
-
Radical cell therapy trial aims to tame uncontrollable lupus
Disease control Not yet recruitingThe purpose of this clinical trial is to learn if CD19/BCMA CAR-T works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the CD19/BCMA CAR-T cell product. The main questions it aims to answer are: 1. What CAR-T-related adverse events (AEs) …
Phase: EARLY_PHASE1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Breakthrough depression treatment enters final testing phase
Disease control Recruiting nowThe purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
Phase: PHASE3 • Sponsor: Cybin IRL Limited • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Doctors test poop transplants to save lives from deadly sepsis lung damage
Disease control Recruiting nowSepsis is a systemic inflammatory response syndrome triggered by infection, and it is a common critical illness in clinical practice, often leading to multiple organ dysfunction. Among these, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are among the mos…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai University of Traditional Chinese Medicine • Aim: Disease control
Last updated Apr 15, 2026 16:14 UTC
-
Brain cancer breakthrough? radiation seeds in surgery tested in major trial
Disease control Recruiting nowThis is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation of Arm A:Arm B. * A Perioperative/Operati…
Phase: PHASE3 • Sponsor: GT Medical Technologies, Inc. • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
Personalized cell transplant offers new hope for High-Risk blood cancer patients
Disease control Recruiting nowThis study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunothe…
Phase: PHASE2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Apr 06, 2026 14:17 UTC
-
New hope for rare lung cancer: targeted pill may outperform standard care
Disease control Recruiting nowThe hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment. The main benefit concerns patient access to tepotinib. There is currently no access to …
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
New hope for Tough-to-Treat ovarian cancer
Disease control Recruiting nowThe purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 13, 2026 20:09 UTC